David A. Siegel Zai Lab LTD Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q4 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Zai Lab LTD stock. As of the latest transaction made, Two Sigma Advisers, LP holds 18,200 shares of ZLAB stock, worth $662,844. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,200

Previous 14,000 30.0%

Holding current value

$662,844

Previous $337,000 41.25%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$24.61 - $33.18 $103,362 - $139,356	4,200 Added 30.0%	18,200 $476,000
Q3 2024 Nov 14, 2024	BUY	$16.25 - $24.14 $227,500 - $337,960	14,000 New	14,000 $337,000
Q2 2022 Aug 15, 2022	SELL	$23.14 - $49.68 $955,682 - $2.05 Million	-41,300 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$27.77 - $64.4 $2.17 Million - $5.02 Million	-78,000 Reduced 65.38%	41,300 $1.82 Million
Q4 2021 Feb 14, 2022	BUY	$54.9 - $105.21 $5.73 Million - $11 Million	104,300 Added 695.33%	119,300 $7.5 Million
Q3 2021 Nov 15, 2021	BUY	$105.0 - $178.37 $1.41 Million - $2.39 Million	13,400 Added 837.5%	15,000 $1.58 Million
Q2 2021 Aug 16, 2021	SELL	$125.11 - $180.0 $1.31 Million - $1.89 Million	-10,500 Reduced 86.78%	1,600 $283,000
Q1 2021 May 17, 2021	BUY	$126.27 - $191.71 $618,723 - $939,379	4,900 Added 68.06%	12,100 $1.62 Million
Q4 2020 Feb 16, 2021	BUY	$81.94 - $135.34 $589,968 - $974,448	7,200 New	7,200 $974,000
Q3 2020 Nov 16, 2020	SELL	$73.3 - $89.48 $749,492 - $914,933	-10,225 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$48.82 - $82.53 $499,184 - $843,869	10,225 New	10,225 $840,000

Others Institutions Holding ZLAB

# of Institutions

146

Shares Held

53M

Call Options Held

103K

Put Options Held

439K

View Full List

About Zai Lab Ltd

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $3.57B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

More about ZLAB

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account